Linker Information
General Information of This Linker
Linker ID |
LIN0DLJQE
|
|||||
---|---|---|---|---|---|---|
Linker Name |
Tetrazine-PEG5-Val-Ala-PABC
|
|||||
Linker Type |
Cathepsin-cleavable linker
|
|||||
Antibody-Linker Relation |
Cleavable
|
|||||
Structure | ||||||
Formula |
C37H52N8O10
|
|||||
Isosmiles |
CC(NC(=O)C(NC(=O)CCOCCOCCOCCOCCOCCC(=O)Nc1ccc(-c2nncnn2)cc1)C(C)C)C(=O)Nc1ccc(CO)cc1
|
|||||
InChI |
InChI=1S/C37H52N8O10/c1-26(2)34(37(50)40-27(3)36(49)42-31-8-4-28(24-46)5-9-31)43-33(48)13-15-52-17-19-54-21-23-55-22-20-53-18-16-51-14-12-32(47)41-30-10-6-29(7-11-30)35-44-38-25-39-45-35/h4-11,25-27,34,46H,12-24H2,1-3H3,(H,40,50)(H,41,47)(H,42,49)(H,43,48)
|
|||||
InChIKey |
RJLYSRPTZAKHPQ-UHFFFAOYSA-N
|
|||||
Pharmaceutical Properties |
Molecule Weight
|
768.869
|
Polar area
|
234.34
|
||
Complexity
|
55
|
xlogp Value
|
1.5118
|
|||
Heavy Count
|
55
|
Rot Bonds
|
27
|
|||
Hbond acc
|
14
|
Hbond Donor
|
5
|
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
T-CpHK-Tet-ADC [Investigative]
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.30 nM
|
High HER2 expression (HER2+++) | ||
Method Description |
ADCs were subjected to cytotoxicity assays to confirm potency toward cell lines with high and low HER2 expression.
|
||||
In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.40 nM
|
High HER2 expression (HER2+++) | ||
Method Description |
ADCs were subjected to cytotoxicity assays to confirm potency toward cell lines with high and low HER2 expression.
|
||||
In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
68.00 nM
|
Moderate HER2 expression (HER2++) | ||
Method Description |
ADCs were subjected to cytotoxicity assays to confirm potency toward cell lines with high and low HER2 expression.
|
||||
In Vitro Model | Invasive breast carcinoma | ZR-75-1 cells | CVCL_0588 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.